Suzanne Racz, PA
Physician Assistant · Dallas, TXNPI 1629302542
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,420 of the $32,346 with a category attached, or 60.0%. UCB, Inc. accounts for 94.7% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $12,669, 9.1 times the $1,397 reported in 2021. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $212.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$31K
- Livanova USA, Inc.$589
- SK Life Science, Inc.$325
- AbbVie$180
- Neurelis, Inc.$138
- Sumitomo Pharma America, Inc.$106
- plus $382 from 10 others
What the payments were for
- Consulting fees$6,48020%
- Speaking & faculty fees$19,42060%
- Travel & lodging$3,74612%
- Food & beverage$2,6998%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 100 | $30,627 |
| Livanova USA, Inc. | 4 | $589 |
| SK Life Science, Inc. | 5 | $325 |
| AbbVie(2 entities) | 11 | $180 |
| Neurelis, Inc. | 5 | $138 |
| Sumitomo Pharma America, Inc. | 7 | $106 |
| Merz Pharmaceuticals, LLC | 3 | $100 |
| Genentech USA, Inc. | 3 | $45 |
| Novartis | 3 | $44 |
| Adamas Pharmaceuticals, Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Johnson & Johnson | 3 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Biogen | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| EMD Serono, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$11,824
- Nayzilam$10,688
- Briviact$6,602
- VNS Therapy$403
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$115
How this compares
$32,346 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 171 | $254,080 |
| KeppraLevetiracetam | 24 | $53,719 |
| XcopriCenobamate | 50 | $52,047 |
| AptiomEslicarbazepine Acetate | 28 | $51,099 |
| Lacosamide | 244 | $41,358 |
| TopamaxTopiramate | 24 | $33,499 |
| Levetiracetam | 443 | $29,393 |
| NayzilamMidazolam | 19 | $25,411 |
| Clobazam | 125 | $16,783 |
| Carbamazepine ErCarbamazepine | 141 | $16,140 |
| Levetiracetam ErLevetiracetam | 86 | $7,922 |
| CarbatrolCarbamazepine | 14 | $4,102 |
| Divalproex Sodium | 55 | $3,951 |
| Gabapentin | 111 | $3,433 |
| Topiramate | 155 | $3,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam | $30,627 | $279,491190 claims |
| SK Life Science, Inc.Xcopri | $325 | $52,04750 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $38 | $51,09928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Dallas
- Cynthia TrickettDallas$1.3M
- Michael WhiteDallas$276K
- Sofia NeicherilDallas$62K
- Shawn SommerladDallas$53K
- Katherine TurnerDallas$43K
- Tori BurnsDallas$39K
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Brooke HodnickSouthlake$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.